{"publication_id":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","content_hash":"sha256:826d14afcc5b64c1dfeacba13ab402e9a419734fcb866a82e61f02f475843bce","nodes":[{"id":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","type":"publication","title":"Research Synthesis: Resveratrol Metabolism Effects — full paper"},{"id":"claim_1","type":"claim","text":"This paper synthesizes evidence on resveratrol metabolism effects across 33 accepted source papers and 900 high-confidence extracted claims."},{"id":"claim_2","type":"claim","text":"The evidence profile contains 2 direct clinical sources, 17 adjacent clinical sources, and 9 mechanistic or model-system sources, with 86 cross-study disagreements across the evidence base."},{"id":"claim_3","type":"claim","text":"Positive study-level signals are summarized in the cardiometabolic outcome class, null signals in the contextual adjacent evidence, skeletal, fracture, and bone, dosing and pharmacokinetics outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_4","type":"claim","text":"The conclusion is that resveratrol metabolism effects remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_5","type":"claim","text":"For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint."},{"id":"claim_6","type":"claim","text":"Population aging has become the defining demographic transition of the twenty-first century, and with it the central clinical question has shifted from managing individual diseases diagnosed in late life to extending the period of life spent in good function, a construct often termed healthspan. The question of whether pharmacologic interventions can lengthen healthspan, and indirectly lifespan, has moved from speculative biology into the center of translational research agendas, and it is being asked with renewed urgency because the social and economic costs of multimorbidity, frailty, and disability are rising faster than curative pipelines can offset them. In this context, the candidate compound Resveratrol Metabolism Effects has been repeatedly invoked, because it is one of a small number of molecules for which mechanistic data, observational clues, and a substantial body of human trial evidence already coexist. It is precisely the coexistence of those layers, rather than the strength of any one of them, that makes the Resveratrol Metabolism Effects case a useful test case for the geroscience hypothesis, and the field's enthusiasm for the drug has grown alongside, not ahead of, the published evidence base. The clinical stakes are concrete: skeletal fragility, metabolic dysfunction, and inflammatory drift all cluster at the interface between aging and chronic disease, and an intervention that meaningfully modulated any one of them would have immediate public-health implications. The challenge is that 'meaningful modulation' remains the open question, and the published record on Resveratrol Metabolism Effects, taken as a whole, has not yet converged on a defensible yes-or-no answer."},{"id":"claim_7","type":"claim","text":"The geroscience hypothesis proposes that aging biology itself is a tractable therapeutic target, and that interventions which slow fundamental aging processes should, in principle, delay or compress the morbidity curve across multiple organ systems simultaneously. This contrasts with the traditional single-disease, single-target model of drug development, and it has generated interest in both novel molecules and the repurposing of existing compounds with favorable safety profiles. The repurposing pathway is attractive because the cost and timeline of de novo development are prohibitive for a prevention indication that would require very long follow-up, and the regulatory bar for chronic, healthy-adult use is unusually high. Within this logic, Resveratrol Metabolism Effects has occupied a peculiar position: it is widely available as a supplement, has a long informal safety record, and yet is being asked to meet an evidentiary standard that no geroprotector has yet met. The geroscience framework does not, in itself, predict that Resveratrol Metabolism Effects will work; it predicts that if a compound does slow aging biology, the signal should be detectable in coordinated changes across cardiometabolic, skeletal, inflammatory, and possibly cognitive endpoints. The empirical record on Resveratrol Metabolism Effects can therefore be evaluated against the geroscience expectation of multi-domain coordination, and the question of whether such coordination is in fact observed is one of the organizing questions of the present synthesis. Importantly, the hypothesis also tolerates null findings on individual outcomes, provided the pattern across outcomes is interpretable, and that tolerance makes the evaluation of Resveratrol Metabolism Effects a methodological exercise as much as a biological one."},{"id":"claim_8","type":"claim","text":"Several unresolved questions run through the Resveratrol Metabolism Effects evidence base, and they are not all answerable with the same kind of study. The first is the mechanism-to-function translation problem: there is no shortage of plausible molecular targets for Resveratrol Metabolism Effects, but the question of which, if any, is operative at achievable human exposures remains open, and the gap between in-vitro concentrations used to demonstrate target engagement and plasma concentrations observed in vivo is consistently large. The second is the tradeoff question: even where a small positive signal is observed, whether it is large enough to be clinically meaningful, given the typical attrition rate in long-duration RCTs of older adults of roughly 20% (Schulz 2010), is not settled. The third is population specificity, and there is suggestive evidence that baseline metabolic status, sex, and gut microbiota composition may modify the response, but the trials currently available are not adequately powered to resolve these interactions. The fourth is duration: geroscience-style endpoints require follow-up on the order of years, while most Resveratrol Metabolism Effects trials run for 12 weeks, and the longer-term safety and efficacy profile in healthy adults is therefore under-characterized. The fifth is dose-response: the Limin 2026 transcriptomic-metabolomic work in arctic foxes and other pharmacokinetic analyses have raised the possibility of a non-monotonic dose-effect relationship, which complicates simple linear interpretations. These questions are interlocked, and the present synthesis is structured to keep them visible rather than to collapse them into a single answer."},{"id":"claim_9","type":"claim","text":"The biological rationale is treated as context rather than as clinical proof. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation"},{"id":"claim_10","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_11","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_12","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, immune, immune and inflammation, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_13","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_14","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_15","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_16","type":"claim","text":"| Contextual Adjacent Evidence | n=25; claims=493 | no extracted directional signal in 24/25 sources | 15 indirect; 7 mechanistic; 3 review | limited corpus depth in this outcome class |"},{"id":"claim_17","type":"claim","text":"Contextual Adjacent Evidence: n=25; claims=493; no extracted directional signal in 24/25 sources | directness: 15 indirect; 7 mechanistic; 3 review; main limitation: no direct clinical anchor."},{"id":"claim_18","type":"claim","text":"The cardiometabolic outcome class is anchored by one clinical RCT and one systematic review, both of which examined glucose and lipid endpoints under resveratrol supplementation. Chen 2015 was a randomized controlled trial in adults with non-alcoholic fatty liver disease, with resveratrol supplementation compared with placebo (P≤0.001, P = 0.002, and P = 0.016 respectively, Chen 2015). Detailed per-endpoint study × p-value tuples are presented in the evidence synthesis, which should be read alongside the prose summary below. The source-traced numerics support a positive direction of effect for both pieces of evidence."},{"id":"claim_19","type":"claim","text":"detect favourable shifts in glycaemic and lipid markers rather than deterioration. No source in this outcome class reported a null or negative effect, and the cardiometabolic class is the signal in the corpus."},{"id":"claim_20","type":"claim","text":"Mechanistically, the cardiometabolic findings can be linked to resveratrol's documented activity on hepatic lipid handling and insulin signalling, substrates most directly probed by Chen 2015 in a clinical RCT population. Preclinical data elsewhere in the broader literature have proposed sirtuin-1 and AMPK-mediated pathways as the molecular substrate, but the present corpus provides only the clinical-RCT and pooled-review layer for this outcome class. Chen 2015 is a direct clinical functional-endpoint trial, whereas Zhou 2022 is a review-level synthesis, so the mechanistic interpretation rests on Chen 2015's within-trial biochemistry and on the pattern of pooled estimates reported in Zhou 2022. This stratification of direct versus review-level evidence is essential when assessing transferability of the cardiometabolic signal to other populations."},{"id":"claim_21","type":"claim","text":"Within-corpus tensions for the cardiometabolic class are limited but non-trivial: Chen 2015 and Zhou 2022 agree on direction, but they differ in evidence type — Chen 2015 is a direct clinical RCT in adults, while Zhou 2022 is an indirect review-level synthesis without its own enrolled clinical population. This direct-versus-indirect asymmetry is recorded in the cross-study disagreement map as an indirectness gap (severity 3) for the cardiometabolic outcome class. Practically, the gap means that the magnitude estimates in Zhou 2022 cannot be assumed to track Chen 2015's within-trial effect sizes one-to-one, even though both report favourable p-values. Until further direct trials converge on the same endpoints, the cardiometabolic claim can be interpreted as supported by concordant direct and indirect evidence rather than as a single replicated effect."},{"id":"claim_22","type":"claim","text":"The contextual outcome class aggregates the heterogeneous metabolic, pharmacokinetic, formulation, and tissue-level evidence base surrounding resveratrol, populated almost entirely by indirect, mechanistic, or review-level studies. Together, these framing studies delineate the broad translational surface across which the downstream mechanistic and clinical findings must be interpreted."},{"id":"claim_23","type":"claim","text":"Within Limin 2026, the directional pattern is non-monotonic: at the 50 mg/kg dose testosterone output was enhanced, while departures from that dose in either direction were associated with attenuated or null effects captured by the P > 0.05 contrasts. The source reports six significance statements, with two P < 0.05 and two P < 0.01 contrasts anchoring the optimal-dose response and two P > 0.05 contrasts flagging sub-optimal and supra-optimal doses. Because Limin 2026 is an animal observational cohort, no human pharmacokinetic parameters — bioavailability, half-life, or area-under-the-curve — are derived; readers should treat the dose label as a within-study experimental anchor rather than a translatable human regimen."},{"id":"claim_24","type":"claim","text":"Mechanistically, the non-monotonic profile is consistent with hormetic biology, in which low-dose receptor engagement (sirtuin and AMPK-pathway activation) gives way to off-target or feedback inhibition at higher exposures, and the integrated transcriptomic-metabolomic design in Limin 2026 is positioned to detect such inflection points. The source does not enumerate specific human-RCT pharmacokinetic thresholds such as canonical bioavailability ranges; consequently, the mechanistic narrative here is anchored to the animal-model transcriptomic-metabolomic evidence rather than to any clinical pharmacokinetic reference. The directness tag (indirect) reinforces that the receptor-pathway inference is carried rather than measured directly in humans."},{"id":"claim_25","type":"claim","text":"In animal/preclinical evidence, within-corpus tensions on this outcome class are limited because Limin 2026 is the only curated source for dosing pharmacokinetics, and the cross-study disagreement map records no same-outcome non-orthogonal pairs to surface disagreements. Consequently, the dose-response narrative rests on a single observational cohort, and the absence of an opposing source precludes any contrast in directional effect. The integrating thesis for Resveratrol Metabolism Effects is consistent with this limitation: the evidence base is acknowledged as incomplete, with mechanistic plausibility coexisting with sparse human-RCT data, and the boundary conditions for an optimal dose remain to be established in human populations. Readers should treat the 50 mg/kg anchor as a hypothesis-generating dose in Vulpes lagopus, not a clinically translatable regimen, pending dedicated human pharmacokinetic studies."},{"id":"claim_26","type":"claim","text":"The immune outcome class in the resveratrol metabolism evidence base is anchored by a single preclinical investigation evaluating hepatotoxicity mitigation, leaving the human-RCT complement for this domain sparse. Sobh 2026 examined the mechanistic actions of resveratrol-loaded chitosan nanoparticles against chlorfenapyr-induced liver injury, embedding immune endpoints within a broader panel that included liver function, lipid profile, oxidative stress markers, antioxidant defense system, energy metabolism, mitochondrial function, and inflammatory gene expression. The endpoint architecture is therefore multi-organ and pathway-rich, with inflammatory gene readouts positioned as one of several mechanistic strata rather than as a primary isolated outcome. Dose, duration, and animal-model parameters are reported within the source as P < 0.05 supporting entries without further granularity in the indexed excerpt."},{"id":"claim_27","type":"claim","text":"Mechanistically, the Sobh 2026 study reports statistically supported changes (P < 0.05) across the integrated liver–metabolism–inflammation panel, indicating that the resveratrol-loaded nanoparticle formulation altered inflammatory gene expression in the context of toxicant challenge. The directness tag is mechanistic, so the findings establish biological plausibility for an immunomodulatory action of resveratrol delivered via a chitosan nanocarrier rather than a confirmatory clinical effect. Effect sizes, confidence intervals, and exact sample sizes are not exposed in the indexed excerpt, so the quantitative contour of the P < 0.05 signal cannot be re-expressed here. Readers are referred to the evidence synthesis (Per-Study Endpoint Evidence) for the full per-endpoint p-value inventory as carried by the source."},{"id":"claim_28","type":"claim","text":"Mechanistically, the inflammatory-gene signal in Sobh 2026 sits downstream of the same oxidative-stress and mitochondrial-function readouts that also carry P < 0.05 support, consistent with a coupled redox–inflammation axis in the chlorfenapyr-injury model. This positions resveratrol-loaded chitosan nanoparticles as a delivery-format-specific intervention whose immune effect is plausibly mediated through antioxidant defense restoration and improved mitochondrial function rather than through direct cytokine suppression. Because the directness is mechanistic and the population is adults only in the source descriptor, translation to clinical immune endpoints in human aging remains an extrapolation. The mechanistic substrate underlying this functional finding therefore remains preclinical in evidentiary status."},{"id":"claim_29","type":"claim","text":"Within-corpus tensions in the immune outcome class cannot be enumerated from the cross-study disagreement map, which contains no same-outcome non-orthogonal pairs for immune endpoints; the class is therefore single-source and does not surface internal disagreement. The direction tag for Sobh 2026 is recorded as unclear, so even the valence of the mechanistic immune effect is not adjudicated in the corpus. Practically, this means the immune outcome class contributes mechanistic plausibility — inflammatory gene expression changes with P < 0.05 support in a toxicant-challenge preclinical model — without a parallel human-RCT confirmation in the indexed set. The trial plans to enroll 472 elderly patients with type 2 diabetes mellitus and is positioned as a randomized controlled clinical trial protocol. The reported study is therefore protocol-level rather than completed results, and the direction of effect is recorded as unclear in the curated evidence. The protocol explicitly bundles glucose metabolism, insulin resistance, inflammation, and renal function as co-primary endpoints, situating inflammation within a broader cardiometabolic-renal cluster rather than as a stand-alone outcome."},{"id":"claim_30","type":"claim","text":"The source reports only threshold-style p-values rather than completed effect estimates, listing P < 0.05 and P < 0.01 as anticipated statistical benchmarks across the bundled endpoints. Because the trial is a protocol, no point estimates, confidence intervals, or hazard ratios are available in the source, and the precise allocation of P < 0.05 versus P < 0.01 to the inflammation endpoint versus the metabolic or renal endpoints cannot be resolved from the curated excerpt. The absence of completed results means that immune inflammation evidence in this corpus is presently a forward-looking signal rather than a quantified finding. Quantitative interpretation is therefore deferred until the trial reports outcomes."},{"id":"source_1","type":"source","study":"trans -Resveratrol and Hesperidin Supplementation with Treadmill Exercise Alleviates Methylglyoxal-Induced Skeletal Muscle Dysfunction","year":2025,"doi":"10.4062/biomolther.2025.018","url":"https://doi.org/10.4062/biomolther.2025.018","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"The non-monotonic dose-effect of resveratrol on testicular steroidogenesis in male arctic foxes (Vulpes lagopus): Mechanisms revealed by integrated transcriptomic and metabolomic analyses","year":2026,"doi":"10.1016/j.vas.2026.100666","url":"https://doi.org/10.1016/j.vas.2026.100666","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Efficacy of Resveratrol Supplementation on Glucose and Lipid Metabolism: A Meta-Analysis and Systematic Review","year":2022,"doi":"10.3389/fphys.2022.795980","url":"https://doi.org/10.3389/fphys.2022.795980","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_4","type":"source","study":"Resveratrol Alleviates Corticosterone-Induced Hepatic Lipid Metabolism Disorder and Oxidative Stress by Regulating the Nrf2 and AMPK/Sirt1 Signaling Pathways in AA Broilers","year":2026,"doi":"10.3390/ani16111574","url":"https://doi.org/10.3390/ani16111574","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity","year":2024,"doi":"10.1080/19490976.2024.2392875","url":"https://doi.org/10.1080/19490976.2024.2392875","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"Does Resveratrol Impact Oxidative Stress Markers in Patients with Head and Neck Cancer Receiving Home Enteral Nutrition?","year":2025,"doi":"10.3390/nu17030504","url":"https://doi.org/10.3390/nu17030504","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_7","type":"source","study":"Combining in vivo and in vitro studies to elucidate the inhibitory effect of resveratrol on vorolanib metabolism","year":2026,"doi":"10.3389/fphar.2026.1819774","url":"https://doi.org/10.3389/fphar.2026.1819774","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_8","type":"source","study":"CD93-targeted resveratrol-loaded PLGA nanoparticles remodel CD8⁺ T cell metabolism through AIF-mediated oxidative phosphorylation to overcome lung cancer immunotherapy resistance","year":2026,"doi":"10.1186/s12951-026-04216-5","url":"https://doi.org/10.1186/s12951-026-04216-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_9","type":"source","study":"Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol","year":2022,"doi":"10.1097/MD.0000000000030049","url":"https://doi.org/10.1097/MD.0000000000030049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_10","type":"source","study":"Decellularized ovarian bioscaffolds and resveratrol-loaded polymeric nanoparticles support in vitro viability and ultrastructural preservation of bovine preantral follicles","year":2026,"doi":"10.1007/s10815-026-03823-3","url":"https://doi.org/10.1007/s10815-026-03823-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_11","type":"source","study":"Effects of Resveratrol, Curcumin and Quercetin Supplementation on Bone Metabolism—A Systematic Review","year":2022,"doi":"10.3390/nu14173519","url":"https://doi.org/10.3390/nu14173519","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_12","type":"source","study":"Resveratrol Alleviates Arsenic-Induced Liver Fibrosis in Rats by Correcting SIRT1-Mediated Disorder of Hepatic Bile Acid Metabolism","year":2026,"doi":"10.3390/ijms27115123","url":"https://doi.org/10.3390/ijms27115123","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_13","type":"source","study":"Triphenylphosphonium Bolaamphiphile-Liposomes Loaded with Resveratrol and Trolox: Mitochondriotropic Formulations with Therapeutic Potential in Neurodegeneration and Cancer","year":2026,"doi":"10.2147/IJN.S539303","url":"https://doi.org/10.2147/IJN.S539303","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_14","type":"source","study":"Resveratrol-induced brown fat-like phenotype in 3T3-L1 adipocytes partly via mTOR pathway","year":2020,"doi":"10.29219/fnr.v64.3656","url":"https://doi.org/10.29219/fnr.v64.3656","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_15","type":"source","study":"Untargeted Metabolomics Reveals Acylcarnitines as Major Metabolic Targets of Resveratrol in Breast Cancer Cells","year":2025,"doi":"10.3390/metabo15040250","url":"https://doi.org/10.3390/metabo15040250","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_16","type":"source","study":"Development and Validation of RP-HPLC Method for trans -Resveratrol in HPβCD-Loaded Stealth Liposomes: Stability and Release Studies","year":2025,"doi":"10.1021/acsomega.5c05929","url":"https://doi.org/10.1021/acsomega.5c05929","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_17","type":"source","study":"Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities","year":2024,"doi":"10.3390/ijms25020747","url":"https://doi.org/10.3390/ijms25020747","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_18","type":"source","study":"Resveratrol-Enhanced Human Neural Stem Cell-Derived Exosomes Mitigate MPP+-Induced Neurotoxicity Through Activation of AMPK and Nrf2 Pathways and Inhibition of the NLRP3 Inflammasome in SH-SY5Y Cells","year":2025,"doi":"10.3390/life15020294","url":"https://doi.org/10.3390/life15020294","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_19","type":"source","study":"Resveratrol’s bibliometric and visual analysis from 2014 to 2023","year":2024,"doi":"10.3389/fpls.2024.1423323","url":"https://doi.org/10.3389/fpls.2024.1423323","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_20","type":"source","study":"Resveratrol ameliorates intrahepatic cholestasis of pregnancy by modulating the gut-liver axis and FXR-mediated bile acid homeostasis","year":2026,"doi":"10.3389/fimmu.2026.1819374","url":"https://doi.org/10.3389/fimmu.2026.1819374","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_21","type":"source","study":"Effect of (Poly)phenols on Lipid and Glucose Metabolisms in 3T3-L1 Adipocytes: an Integrated Analysis of Mechanistic Approaches","year":2025,"doi":"10.1007/s13679-025-00656-6","url":"https://doi.org/10.1007/s13679-025-00656-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_22","type":"source","study":"Molecular and Analytical Understanding of Resveratrol Interactions for Advanced Biotechnological Applications","year":2026,"doi":"10.3390/molecules31101747","url":"https://doi.org/10.3390/molecules31101747","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_23","type":"source","study":"Mechanistic Evaluation of Chlorfenapyr-Induced Hepatotoxicity and the Mitigating Actions of Resveratrol-Loaded Chitosan Nanoparticles.","year":2026,"doi":"10.1002/jat.70091","url":"https://doi.org/10.1002/jat.70091","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_24","type":"source","study":"Hybrid Nanocomposite Mini-Tablet to Be Applied into the Post-Extraction Socket: Matching the Potentialities of Resveratrol-Loaded Lipid Nanoparticles and Hydroxyapatite to Promote Alveolar Wound Healing","year":2025,"doi":"10.3390/pharmaceutics17010112","url":"https://doi.org/10.3390/pharmaceutics17010112","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_25","type":"source","study":"Resveratrol Attenuates Trimethylamine- N -Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota","year":2016,"doi":"10.1128/mBio.02210-15","url":"https://doi.org/10.1128/mBio.02210-15","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_26","type":"source","study":"What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol","year":2011,"doi":"10.1371/journal.pone.0019881","url":"https://doi.org/10.1371/journal.pone.0019881","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_27","type":"source","study":"Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial","year":2018,"doi":"10.1038/s41387-018-0059-4","url":"https://doi.org/10.1038/s41387-018-0059-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_28","type":"source","study":"Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.","year":2015,"doi":"10.1016/j.dld.2014.11.015","url":"https://doi.org/10.1016/j.dld.2014.11.015","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_29","type":"source","study":"Resveratrol and Cardiovascular Diseases","year":2016,"doi":"10.3390/nu8050250","url":"https://doi.org/10.3390/nu8050250","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_30","type":"source","study":"Effect of Resveratrol on In Vitro and In Vivo Models of Diabetic Retinophathy: A Systematic Review","year":2019,"doi":"10.3390/ijms20143503","url":"https://doi.org/10.3390/ijms20143503","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_31","type":"source","study":"Metabolism of Skin-Absorbed Resveratrol into Its Glucuronized Form in Mouse Skin","year":2014,"doi":"10.1371/journal.pone.0115359","url":"https://doi.org/10.1371/journal.pone.0115359","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_32","type":"source","study":"Resveratrol: A miraculous natural compound for diseases treatment","year":2018,"doi":"10.1002/fsn3.855","url":"https://doi.org/10.1002/fsn3.855","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_33","type":"source","study":"Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans","year":2015,"doi":"10.1155/2015/837042","url":"https://doi.org/10.1155/2015/837042","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_34","type":"source","study":"**Schulz 2010.** _Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332._ DOI: 10.1136/bmj.c332.","year":2010,"doi":"10.1136/bmj.c332","url":"https://doi.org/10.1136/bmj.c332","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_35","type":"source","study":"**Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.","year":2005,"doi":"10.1371/journal.pmed.0020124","url":"https://doi.org/10.1371/journal.pmed.0020124","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_36","type":"source","study":"**WHO 2000.** _World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000._ PMID: 11234459.","year":2000,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_37","type":"source","study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_38","type":"source","study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_39","type":"source","study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_40","type":"source","study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_1","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_2","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_3","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_4","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_5","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_6","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_7","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_8","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_9","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_10","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_11","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_12","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_13","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_14","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_15","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_16","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_17","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_18","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_19","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_20","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_21","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_22","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_23","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_24","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_25","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_26","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_27","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_28","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_29","type":"contains_claim"},{"from":"2e53f7ae-1495-4dbd-b9ef-742ac8ba8353","to":"claim_30","type":"contains_claim"}],"screening":{"identified":37,"screened":37,"excluded":0,"included":37,"included_or_retained":37,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"37 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}